NCT05768490View on ClinicalTrials.gov

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

PHASE3RecruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Brain MetastasesRadiotherapyEGFR Activating Mutation
Interventions
RADIATION

brain radiotherapy

Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.

DRUG

Almonertinib

almonertinib po 110mg QD

Trial Locations (1)

510000

RECRUITING

Sun-Yat-Sen university, Guangdong

All Listed Sponsors
lead

Sun Yat-sen University

OTHER